



PATENT
Customer No. 22,852
Attorney Docket No. 3804.1596-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Divisional Application of:)
)
Manfred BOHN et al.) Group Art Unit: 1614
)
Application No.: 10/606,229) Examiner: Unassigned
(Div. of Appl'n No.: 09/077,194))
)
Filed: June 26, 2003)
)
For: USE OF 1-HYDROXY-2-PYRIDONES FOR)
THE TREATMENT OF SEBORRHEIC)
DERMATITIS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the information set forth below. This Supplemental Information Disclosure Statement is being filed before the first Office Action on the merits.

Applicants call the Examiner's attention to the following English-language summary of the previously submitted German-language article by Schöfer. This summary was provided by the Applicants.

The Therapy of Seborrheic Eczema During HIV-infections

"20 of 29 HIV-patients having seborrheic eczema showed an improvement after 1 week treatment with a crème containing 2 % ketoconazole. After 4 weeks of treatment 86 % of the patients showed symptom improvement. Treatment with the crème alone showed similar improvements. Differences in the therapy between HIV-infected patients showing

seborrheic eczema and immune competent patients could not be detected."

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that the submitted information is material or constitutes "prior art." If the Examiner applies any of the submitted information as prior art against any claim in the application and Applicants determine that the cited information does not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such information.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the submitted information, should that information be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: January 14, 2004

By: 
Jeremy M. Stipkala
Reg. No. 44,359

643246